Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAG | P61981 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | APEX1 | P27695 | 2/20 | 0.60 |
| ▸ | THPO | P40225 | 2/20 | 0.60 |
| ▸ | RGS12 | O14924 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668882 | 0.81 | GAA (0.72) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL29446278 | 0.81 | GAA (0.72) | YWHAGKDM4EGAAMAPTHIF1A | |
| Methyl Alcohol SCHEMBL27946196 | 0.79 | GAA (0.70) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL4140693 | 0.78 | YWHAG (0.68) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL31741653 | 0.78 | YWHAG (0.68) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL22982989 | 0.77 | KDM4E (0.72) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL31618868 | 0.77 | KDM4E (0.72) | YWHAGKDM4EGAAMAPTHIF1A | |
| SCHEMBL20847663 | 0.77 | YWHAG (0.76) | YWHAGKDM4EGAAMAPTHIF1A | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL29382155 | 0.75 | GAA (1.00) | YWHAGKDM4EGAAMAPTHIF1A | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL36348 | 0.75 | GAA (1.00) | YWHAGKDM4EGAAMAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125986-B2 | Penicillanic acid derivative compounds and methods of making | SOUTHERN METHODIST UNIVERSITY FOUNDATION FOR RESEARCH (US) | 2006-10-24 | — | — | US | claimed |
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-11-04 | — | — | US | claimed |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | ALAMX L.L.C. | 2003-11-20 | — | — | US | claimed |
| WO-2003087105-A1 | INHIBITORS OF SERINE AND METALLO-ß-LACTAMASES | ALAMX, L.L.C. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030036541-A1 | Beta-lactamase inhibiting compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-20 | — | — | US | claimed |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | claimed |
| JP-2002542249-A | — | — | 2002-12-10 | — | — | JP | claimed |
| US-6436398-B2 | ADMINISTERING A BETA-LACTAM ANTIBIOTIC WITH A BETA-LACTAMASE INHIBITING COMPOUND SUCH AS BENZHYDRYL 2-BETA-(CHLOROACETOXY-METHYL)-6-((Z)-(TERT-BUTOXYCARBONYL)METHYLENE) PENICILLINATE TO TREAT BETA-LACTAM RESISTANT BACTERIAL INFECTIONS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-08-20 | — | — | US | claimed |
| US-6407091-B1 | CEPHALOSPORIN DERIVATIVES; TREATING MICROBIAL AND ANTIBIOTIC RESISTANCE | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-06-18 | — | — | US | claimed |
| EP-0966471-B1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | RES CORP TECHNOLOGIES INC (US) | 2002-06-12 | — | — | EP | claimed |
| EP-1169323-A1 | BETA-LACTAMASE INHIBITING COMPOUNDS | Research Corporation Technologies, Inc (US) | 2002-01-09 | — | — | EP | claimed |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-09-13 | — | — | US | claimed |
| US-6156745-A | 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-12-05 | — | — | US | claimed |
| WO-2000063213-A1 | BETA-LACTAMASE INHIBITING COMPOUNDS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-10-26 | — | — | WO | claimed |
| EP-0966471-A1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | Research Corporation Technologies, Inc (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-7125986-B2 | Penicillanic acid derivative compounds and methods of making | SOUTHERN METHODIST UNIVERSITY FOUNDATION FOR RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1359153-B1 | Beta-lactamase inhibiting compounds | RES CORP TECHNOLOGIES INC (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-0966471-A1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | Research Corporation Technologies, Inc (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036541-A1 | Beta-lactamase inhibiting compounds | MRPL21, CYP51A1, BACE1 | YWHAG 2359/4885KDM4E 888/4885GAA 4/4885 |
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, CYP51A1, RPIA | YWHAG 4241/4885KDM4E 2865/4885GAA 135/4885 |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, RPIA, RPN1 | YWHAG 4301/4885KDM4E 3042/4885GAA 206/4885 |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | SRR, BACE1, PRSS1 | YWHAG 3093/4885KDM4E 1840/4885GAA 93/4885 |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | IDUA, NAALAD2, GLA | YWHAG 3222/4885KDM4E 2469/4885GAA 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.